Overview

Relative Bioavailability of Single Doses of Dabigatran Etexilate in Healthy Volunteers

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Study to investigate whether and to what extent the suggested P-glycoprotein (P-gp) inducer rifampicin affects plasma exposure of dabigatran.
Phase:
Phase 1
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Dabigatran
Rifampin